Skip to content
OpenCapital
Get started

Aurinia Pharmaceuticals AUPH Deferred compensation and other noncurrent liabilities

Deferred compensation and other noncurrent liabilities at other companies

CVB Financial logo
CVB FinancialCVBF
$23.43M+1.6%
Tootsie Roll Industries logo
Tootsie Roll IndustriesTR
$118.96M+12.9%
UFP Technologies logo
UFP TechnologiesUFPT
$6.74M+4.7%
Exponent logo
ExponentEXPO
$128.21M+14.6%
Marriott Vacations Worldwide logo
Marriott Vacations WorldwideVAC
$214M+15.1%
Vornado Realty logo
Vornado RealtyVNO
$112.76M+1.5%

Other financials

Income statement

See full
Revenue$77.7M+24.4%
Gross profit$71.2M+32.1%
Operating income$41.4M+89.6%
Net income$34.4M+47.2%
EPS (diluted)$0.25+56.3%

Balance sheet

See full
Cash & equivalents$41.0M-38.3%
Total debt$85.2M-7.9%
Total equity$567.6M+62.1%
Total assets$724.0M+43.4%

Cash flow

See full
Operating cash flow$32.6M+2,405%

Valuation

See full
Market cap$2.3B+78.5%
Enterprise value$2.34B+78.3%
P/E7.7×-24.6×
P/S7.7×+2.5×

Profitability

See full
Gross margin89.7%+1.5pp
Operating margin41.7%+29.4pp
Net margin100%+83.9pp

Returns & leverage

See full
Return on equity65%+53.8pp
Debt / equity0.2×-0.1×
Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept auph:DeferredCompensationLiabilityClassifiedNoncurrentAndOtherNoncurrentLiabilities.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's deferred compensation and other noncurrent liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aurinia Pharmaceuticals's deferred compensation and other noncurrent liabilities?
Aurinia Pharmaceuticals (AUPH) reported deferred compensation and other noncurrent liabilities of $6.9M in Q1 2026.
How has Aurinia Pharmaceuticals's deferred compensation and other noncurrent liabilities changed year-over-year?
Aurinia Pharmaceuticals's deferred compensation and other noncurrent liabilities decreased by 39.6% year-over-year, from $11.44M to $6.9M.
What does deferred compensation and other noncurrent liabilities mean?
This represents long-term obligations to employees or executives for compensation that has been earned but is payable beyond the next twelve months. It typically includes deferred bonus plans, retirement benefits, or other long-term incentive arrangements. Tracking this liability provides insight into the company's long-term human capital costs and potential future cash outflows related to executive retention.